Metraipolis › archive › dc_72eacfe148d0

Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kg — Europe PMC PMID:41843763

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41843763
DOI
10.1093/ecco-jcc/jjag011
License (as archived)
solo-consultazione
Archived
2026-10-08T06:57:13.913Z
SHA-256 of the archived text
46f383134938092047a70340ffa78828e47c9aca4997b7fa578eeb6157d3de67
Stable URL of this page
https://metraipolis.com/documento/dc_72eacfe148d0

How to cite

Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kg — Europe PMC PMID:41843763 — Europe PMC (en), https://europepmc.org/article/MED/41843763 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_72eacfe148d0 (Metraipolis archive dc_72eacfe148d0, sha256 46f383134938092047a70340ffa78828e47c9aca4997b7fa578eeb6157d3de67)
BibTeX
@misc{dc72eacfe148d0,
  title = {Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kg — Europe PMC PMID:41843763},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41843763},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_72eacfe148d0; sha256 46f383134938092047a70340ffa78828e47c9aca4997b7fa578eeb6157d3de67},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41843763. Agents can read the archived copy with the MCP tool read_document.